Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT01442792

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01442792
  • EudraCT 2011-001094-58
Other papers using this trial's data
  • Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial Thrombosis and haemostasis, 2015-08 DOI, PubMed 25925992, PMC6374984 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01442792. Randomized; no masking; primary purpose prevention. Start 2011-10-12 (actual); primary completion 2013-01-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention
Acronym
X-PLORER
Condition
Cardiovascular Disease
Intervention (Drug)
UFH
Intervention (Drug)
Rivaroxaban (Xarelto, BAY59-7939)
Intervention (Drug)
Rivaroxaban (Xarelto, BAY59-7939)
Intervention (Drug)
Rivaroxaban (Xarelto, BAY59-7939) and UFH
Lead sponsor
Bayer (class: industry)
Collaborator
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct01442792
Content hash
32508c09228e41b632ecc6241642b9caaaf83053b27942e34c7b879f9d1bf38a